Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference

Rhea-AI Summary

Apyx Medical (NASDAQ:APYX) announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, on Tuesday, August 11, 2026. President and CEO Charlie Goodwin and CFO Matt Hill will join a fireside chat at 2:30pm ET and hold one-on-one investor meetings.

The fireside chat will be available via live webcast, with a replay posted in the Events section of Apyx Medical’s Investor Relations website. Apyx Medical highlights its Renuvion, AYON Body Contouring System, and J-Plasma technologies, which it describes as supported by more than 90 clinical documents and used in cosmetic and hospital surgical markets.

News Market Reaction – APYX

-0.77%

2 alerts

-0.77% Session close to close

$157.18M Market Cap

0.2x Rel. Volume

In the Jul 28 session, APYX declined 0.77%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The July 23 earnings-date notice carried a documented -2.05% 24-hour reaction, adding context that e...

Analysis

The July 23 earnings-date notice carried a documented -2.05% 24-hour reaction, adding context that event scheduling has differed from APYX’s stronger clinical and regulatory precedents; the low short-interest level remains a relevant risk factor to monitor.

Key Figures

Conference edition: 46th annual Conference date: August 11, 2026 Clinical documents: More than 90 clinical documents

3 metrics

Conference edition 46th annual Canaccord Genuity Growth Conference

Conference date August 11, 2026 Management participation in Boston

Clinical documents More than 90 clinical documents Supporting Renuvion and J-Plasma effectiveness

Historical Context

5 past events · Latest: Jul 23 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 23	Earnings date notice	Neutral	-2.0%	Announced second-quarter results release date and conference call schedule.
May 27	Product showcase	Positive	-4.7%	Showcased Renuvion patients and AYON body contouring capabilities at Miami Swim Week.
May 21	Clinical data	Positive	+12.1%	Reported cellulite improvement and tissue-remodeling findings from a 22-patient study.
May 14	Clinical publication	Positive	+13.5%	Reported improved satisfaction and lower revision rates in a 113-patient retrospective study.
May 11	FDA clearance	Positive	+6.8%	Received expanded FDA 510(k) clearance adding power liposuction capability to AYON.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical and regulatory announcements aligned with gains in three of five comparable events, while a promotional announcement and an earnings-date notice diverged with negative reactions.

Key Terms

fda-cleared, electrosurgical

2 terms

fda-cleared regulatory

"The AYON Body Contouring System is an FDA-cleared, groundbreaking"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

electrosurgical technical

"closed loop contouring, electrosurgical capabilities and Renuvion"

Electrosurgical describes tools and procedures that use controlled electric current to cut, seal, or stop bleeding in body tissues during medical procedures, similar to using a heated knife or a precise spark instead of a scalpel. For investors, electrosurgical products matter because they drive sales, device adoption, regulatory reviews, and liability risk in the surgical devices market—factors that affect revenue, profit margins, and company valuations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System^™ (AYON), today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA.

Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate in a fireside chat on Tuesday, August 11, 2026, at 2:30pm ET and will hold one-on-one meetings with investors throughout the day. The fireside chat will be accessible via live webcast here, and a replay will be available on the Events section of Apyx Medical’s Investor Relations website at https://apyxmedical.com/investor_relations/.

About Apyx Medical Corporation:

Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring System^™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com  

FAQ

When will Apyx Medical (NASDAQ:APYX) present at the Canaccord Genuity 46th Annual Growth Conference in 2026?

Apyx Medical will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. According to Apyx Medical, President and CEO Charlie Goodwin and CFO Matt Hill will take part in a fireside chat at 2:30pm ET that day.

How can investors access Apyx Medical’s August 11, 2026 Canaccord fireside chat webcast?

Investors can access Apyx Medical’s August 11, 2026 fireside chat via a live webcast link provided by the company. According to Apyx Medical, a replay of the webcast will also be available in the Events section of its Investor Relations website after the session.

Which Apyx Medical executives will attend the Canaccord Genuity 46th Annual Growth Conference in 2026?

Apyx Medical will be represented by President and Chief Executive Officer Charlie Goodwin and Chief Financial Officer Matt Hill at the 2026 Canaccord conference. According to Apyx Medical, they will participate in a fireside chat and hold one-on-one meetings with investors throughout the day.

What products will Apyx Medical (APYX) highlight to investors around the August 2026 Canaccord conference?

Apyx Medical is a surgical aesthetics company focused on its Renuvion, AYON Body Contouring System, and J-Plasma technologies. According to Apyx Medical, these systems use helium plasma and controlled heat for tissue treatment, with effectiveness supported by more than 90 clinical documents in cosmetic and surgical markets.

What is the AYON Body Contouring System mentioned by Apyx Medical (APYX)?

The AYON Body Contouring System is an FDA-cleared, surgeon-designed body contouring platform from Apyx Medical. According to Apyx Medical, it integrates fat removal, closed loop contouring, electrosurgical capabilities, and Renuvion for tissue contraction to support comprehensive body contouring procedures in a single system.

How does Apyx Medical’s Renuvion and J-Plasma technology support surgical procedures?

Renuvion and J-Plasma provide surgeons with controlled heat delivery to tissue during procedures, according to Apyx Medical. The company states that the effectiveness of these technologies is supported by more than 90 clinical documents and that they are used in cosmetic and hospital surgical markets, respectively.